These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33969)

  • 21. The effect of benztropine mesylate in the rabbit syndrome and tardive dyskinesia.
    Sovner R; Dimascio A
    Am J Psychiatry; 1977 Nov; 134(11):1301-2. PubMed ID: 910992
    [No Abstract]   [Full Text] [Related]  

  • 22. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients.
    Chouinard G; Annable L; Kropsky M
    J Clin Pharmacol; 1978; 18(2-3):148-54. PubMed ID: 24061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Side effects of depot fluphenazines.
    Ayd FJ
    Adv Biochem Psychopharmacol; 1974; 9(0):301-9. PubMed ID: 4599435
    [No Abstract]   [Full Text] [Related]  

  • 25. Antidepressants in the treatment of post-psychotic depression in schizophrenia: drug interactions and other considerations.
    Siris SG; Sellew AP; Frechen K; Cooper TB; Mandell J; Casey E
    Clin Chem; 1988 May; 34(5):837-40. PubMed ID: 3286051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA antigens in drug-induced parkinsonism.
    Metzer WS; Newton JE; Steele RW; Claybrook M; Paige SR; McMillan DE; Hays S
    Mov Disord; 1989; 4(2):121-8. PubMed ID: 2567491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-induced parkinsonism: relationship to age at onset of schizophrenia.
    Sandyk R; Kay SR
    Funct Neurol; 1991; 6(2):151-7. PubMed ID: 1680777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia.
    Hanin B; Lerner Y; Srour N
    Convuls Ther; 1995 Dec; 11(4):271-4. PubMed ID: 8919580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
    Rondot P; Bathien N
    Adv Neurol; 1987; 45():361-6. PubMed ID: 2881446
    [No Abstract]   [Full Text] [Related]  

  • 30. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.
    Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J
    Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
    Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
    Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
    [No Abstract]   [Full Text] [Related]  

  • 32. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
    J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.
    Mindham RH; Lamb P; Bradley R
    Br J Psychiatry; 1977 Jun; 130():581-5. PubMed ID: 326325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism.
    Kelly JT; Zimmermann RL; Abuzzahab FS; Schiele BC
    Pharmacology; 1974; 12(2):65-73. PubMed ID: 4610599
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics.
    Winslow RS; Stillner V; Coons DJ; Robison MW
    Am J Psychiatry; 1986 Jun; 143(6):706-10. PubMed ID: 2872822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rigidity, hyperpyrexia and coma following fluphenazine enanthate.
    Meltzer HY
    Psychopharmacologia; 1973; 29(4):337-46. PubMed ID: 4707025
    [No Abstract]   [Full Text] [Related]  

  • 37. The withdrawal of benztropine mesylate in chronic schizophrenic patients.
    Baker LA; Cheng LY; Amara IB
    Br J Psychiatry; 1983 Dec; 143():584-90. PubMed ID: 6362765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of benztropine mesylate and amantadine HCl in neuroleptic-induced extrapyramidal symptoms.
    Stenson RL; Donion PT; Meyer JE
    Compr Psychiatry; 1976; 17(6):763-8. PubMed ID: 791573
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiparkinson drugs as causal agents in tardive dyskinesia.
    Kiloh LG; Smith JS; Williams SE
    Med J Aust; 1973 Sep; 2(12):591-3. PubMed ID: 4149942
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.